Successful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in ...
NN4101, a first-in-class, connects a fully human anti-c-Kit monoclonal antibody with a vascular endothelial growth factor (VEGF) trap.
The Nobility team consists of serial entrepreneurs, marketing experts, and a team of blockchain wizards. The team is fully transparent, and ‘doxxed', meaning their identities are public. They host ...
Novelty Nobility expands manufacturing pact with AGC Biologics to further develop bispecific drug candidate: Chiba, Japan Tuesday, May 5, 2026, 18:00 Hrs [IST] Novelty Nobility, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results